Investing
1067 Articles
Jim Cramer has touted several DJIA upside calls in 2012, but on Monday’s MAD MONEY on CNBC Cramer touted Merck…
The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking…
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) has been on fire due to the rapid interest of hepatitis C treatments and the bidding of…
US markets opened up slightly this morning and have maintained a slight positive tone for most of the day. Today…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms…
For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at…
As each new year replaces the prior year, 24/7 Wall St. looks at the individual targets on all 30 Dow…
The lineup of the Dogs of the Dow, simply the ten highest dividend yield stocks of the thirty Dow Jones…
We recently gave a full review of the DJIA components we expect to raise their dividend payouts in the weeks…
AuthorDendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment. Unfortunately, PROVENGE sales…
Dividends are still rising and equity and income investors should expect more of the same for 2012. The Walt Disney Company…
China’s factory activity reaches a 32-month low. (Reuters) Merck (NYSE: MRK) pays $950 million to settle Vioxx charges brought by…
Merck (NYSE: MRK) will pay $950 million to settle criminal and civil charges that it inappropriately promoted use of Vioxx, according…
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1…
The economic choppiness is coming to a head with the age of dividend hikes. The pressure is going to remain…
Our top personal finance-related articles today. Your wallet will thank you later.